Best in class? Eli Lilly claims a lead role awaits its CDK 4/6 drug abemaciclib after PhIII success
The pharma giant says their drug abemaciclib garnered promising data in an interim analysis of MONARCH-3, a breast cancer trial that matched their drug with either of two aromatase inhibitors — letrozole or anastrozole — against only the aromatase inhibitor. The full data will be rolled out later, with Lilly limiting itself to the boast that their drug has the potential to be the best-in-class therapy in the likely three-way struggle to come.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
